[Malaria vaccine].
With about 2.2 billion of the world' s population at risk, malaria remains as one of the most infectious disease globally. The failure of existing control strategies necessitates the need for vaccine development. Our efforts have been geared on the development of an effective vaccine using SE36 protein based from the N-terminal domain of Serine Repeat Antigen (SERA5) of Plasmodium falciparum. Immunoepidemiological data underscores the uniqueness of SERA vs. other vaccine candidate, showing a semi-perfect correlation of the naturally induced antibody response to SE36 protein with increased protective immunity in adults and children. GMP-grade SE36 was formulated adsorbed to aluminum hydroxide gel as BK-SE36. Immunological test using squirrel monkeys provided significant protection after P. falciparum challenge infection. No significant safety issues have been identified in healthy, malaria-unexposed adults in a Phase Ia clinical trial in Japan. Cumulative data confirms that the vaccine is safe and highly immunogenic.
Horii
Toshihiro
T
Department of Protozoology, Research Institute for Microbial Diseases, Osaka Univesity.
D000328:Adult; D000536:Aluminum Hydroxide; D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D002648:Child; D017321:Clinical Trials, Phase I as Topic; D015195:Drug Design; D006801:Humans; D008288:Malaria / Q000469:parasitology / Q000517:prevention & control* / Q000635:transmission; D017780:Malaria Vaccines; D010963:Plasmodium falciparum / Q000235:genetics / Q000276:immunology; D017434:Protein Structure, Tertiary; D012453:Saimiri
D000953:Antigens, Protozoan; D017780:Malaria Vaccines; C480167:serine repeat antigen 5, Plasmodium falciparum; D000536:Aluminum Hydroxide